文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Comparison of chemoembolization with CalliSpheres microspheres and conventional chemoembolization in the treatment of hepatocellular carcinoma: a multicenter retrospective study.

作者信息

Liang Bin, Xiang Hua, Ma Cong, Xiong Bin, Ma Yilong, Zhao Chang, Yao Yuanhui, Zhang Zishu, Chen Changyong, Li Haiping, Long Qingyun, Zhou Jun, Luo Chao, Qiu Huaiming, Hu Hongyao, Zhao Hui, Zhou Guofeng, Zheng Chuansheng

机构信息

Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.

Department of Interventional Radiology, Hunan Provincial People's Hospital, Changsha, People's Republic of China.

出版信息

Cancer Manag Res. 2020 Feb 10;12:941-956. doi: 10.2147/CMAR.S187203. eCollection 2020.


DOI:10.2147/CMAR.S187203
PMID:32104076
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7020935/
Abstract

PURPOSE: This study aimed to compare the efficacy and safety between transarterial chemoembolization (TACE) with CalliSpheres microspheres (CSM-TACE) and conventional TACE (cTACE) in patients with hepatocellular carcinoma (HCC). PATIENTS AND METHODS: Three hundred and thirty-five HCC patients receiving CSM-TACE or cTACE were consecutively enrolled in this multi-center, retrospective cohort study, and then divided into CSM-TACE group and cTACE group accordingly. Complete response (CR), objective response (ORR) and disease control response (DCR) was assessed according to mRECIST criteria at 1 month (M1), 3 months(M3) and 6 months(M6) after treatment. Progression-free survival (PFS) and overall survival (OS) were assessed. Liver function indexes and adverse events (AEs) were also evaluated. RESULTS: CR at M3 (=0.020) and ORR at M1 (<0.001), M3 (<0.001) and M6 (=0.017) after treatment were significantly higher in the CSM-TACE compared with cTACE group. DCRs, PFS (25.3 months vs 24.2 months, =0.503) and OS (27.8 months vs 25.3 months, =0.203) were similar between the two groups. CSM-TACE was independently correlated with higher ORR at M1 (=0.002) and longer OS (=0.023). Abnormal alkaline phosphatase (ALP) (=0.049) was independently associated with lower ORR at M3, and history of alcohol intake (=0.019) and largest nodule size ≥7 cm (=0.015) independently correlated with lower ORR at M6 (=0.015). Largest nodule size ≥7 cm (=0.029) and abnormal albumin (ALB) (=0.046) were independently associated with shorter PFS. Child-Pugh stage B/C (=0.023), abnormal ALB (=0.001), ALP (=0.008) and alpha-fetoprotein (AFP) (=0.005) were independently associated with shorter OS. Most liver function indexes and AEs were similar between the two groups (>0.05), except that ALP (=0.005), total bilirubin (=0.031), pain during procedure (=0.034) and occurrence of fever post(treatment (=0.017) were significantly elevated in the CSM-TACE compared with cTACE group. CONCLUSION: CSM-TACE presents with a better treatment response and similar survival profile compared with cTACE in HCC patients.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4021/7020935/8984077c9f3f/CMAR-12-941-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4021/7020935/fb64fb5a1973/CMAR-12-941-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4021/7020935/f1fe03a85d76/CMAR-12-941-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4021/7020935/990a83f81ec8/CMAR-12-941-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4021/7020935/8984077c9f3f/CMAR-12-941-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4021/7020935/fb64fb5a1973/CMAR-12-941-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4021/7020935/f1fe03a85d76/CMAR-12-941-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4021/7020935/990a83f81ec8/CMAR-12-941-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4021/7020935/8984077c9f3f/CMAR-12-941-g0004.jpg

相似文献

[1]
Comparison of chemoembolization with CalliSpheres microspheres and conventional chemoembolization in the treatment of hepatocellular carcinoma: a multicenter retrospective study.

Cancer Manag Res. 2020-2-10

[2]
Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients.

Clin Res Hepatol Gastroenterol. 2021-3

[3]
Comparison of treatment response, survival and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres® microspheres versus conventional transarterial chemoembolization in treating hepatocellular carcinoma.

J BUON. 2019

[4]
Comparison of treatment efficacy and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres microspheres and conventional transarterial chemoembolization as first-line treatment in hepatocellular carcinoma patients.

Am J Transl Res. 2019-12-15

[5]
Comparison of Treatment Response, Survival Profiles, as Well as Safety Profiles Between CalliSpheres Microsphere Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Huge Hepatocellular Carcinoma.

Front Oncol. 2022-1-21

[6]
Comparison of liver function and safety in hepatocellular cancer patients treated with DEB-TACE and cTACE: a multi-center, retrospective cohort study.

Transl Cancer Res. 2019-9

[7]
Treatment Response, Survival, and Safety of Transarterial Chemoembolization With CalliSpheres Microspheres Versus Conventional Transarterial Chemoembolization in Hepatocellular Carcinoma: A Meta-Analysis.

Front Oncol. 2021-3-16

[8]
Comparison of CalliSpheres microspheres drug-eluting beads and conventional transarterial chemoembolization in hepatocellular carcinoma patients: a randomized controlled trial.

Radiol Oncol. 2023-3-1

[9]
Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history.

Clin Res Hepatol Gastroenterol. 2022-3

[10]
Drug-eluting bead transarterial chemoembolization (TACE) vs conventional TACE in treating hepatocellular carcinoma patients with multiple conventional TACE treatments history: A comparison of efficacy and safety.

Medicine (Baltimore). 2019-5

引用本文的文献

[1]
Drug-eluting beads transarterial chemoembolization vs conventional transarterial chemoembolization in the treatment of hepatocellular carcinoma in adult patients: a systematic review and update meta-analysis of observational studies.

Front Oncol. 2025-2-12

[2]
5-Fluorouracil combined with CalliSphere drug-eluting beads or conventional transarterial chemoembolization for unresectable hepatocellular carcinoma: a propensity score weighting analysis.

Sci Rep. 2024-10-26

[3]
Efficacy and Safety of Transarterial Chemoembolization and Repeated Partial Splenic Embolization for Hepatocellular Carcinoma with Hypersplenism and Thrombocytopenia.

J Hepatocell Carcinoma. 2024-6-11

[4]
Clinical research progress of callisperes of drug-loaded microsphere arterial chemoembolisation in the treatment of solid tumors.

Discov Oncol. 2024-5-13

[5]
Safety and Effectiveness of Transarterial Chemoembolization in Hepatocellular Carcinoma Patients Aged Greater versus Less Than 80 Years.

Clin Interv Aging. 2023

[6]
Construction of pain prediction model for patients undergoing hepatic arterial chemoembolization.

World J Surg Oncol. 2023-3-20

[7]
Comparison of CalliSpheres microspheres drug-eluting beads and conventional transarterial chemoembolization in hepatocellular carcinoma patients: a randomized controlled trial.

Radiol Oncol. 2023-3-1

[8]
Callispheres drug-eluting bead transhepatic artery chemoembolization with oral delivery of sorafenib for the treatment of unresectable liver cancer.

Front Surg. 2022-9-2

[9]
CalliSpheres microsphere transarterial chemoembolization combined with I brachytherapy for patients with non-small-cell lung cancer liver metastases.

Front Oncol. 2022-8-12

[10]
Tumor Response and Nomogram-Based Prognostic Stratification for Hepatocellular Carcinoma After Drug-Eluting Beads Transarterial Chemoembolization.

J Hepatocell Carcinoma. 2022-6-7

本文引用的文献

[1]
Comprehensive Analysis of Factors Affecting Clinical Response and Short-Term Survival to Drug-Eluting Bead Transarterial Chemoembolization for Treatment in Patients With Liver Cancer.

Technol Cancer Res Treat. 2018-1-1

[2]
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.

J Hepatol. 2018-7

[3]
Sustained multiple organ ischaemia after transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma.

Exp Ther Med. 2018-2

[4]
Conventional drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma.

World J Hepatol. 2017-6-28

[5]
Comparison of Triple-Drug Transcatheter Arterial Chemoembolization (TACE) With Single-Drug TACE Using Doxorubicin-Eluting Beads: Long-Term Survival in 313 Patients.

AJR Am J Roentgenol. 2017-7-13

[6]
Albumin-Bilirubin and Platelet-Albumin-Bilirubin Grades Accurately Predict Overall Survival in High-Risk Patients Undergoing Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma.

J Vasc Interv Radiol. 2017-9

[7]
Comparison of pharmacokinetics and drug release in tissues after transarterial chemoembolization with doxorubicin using diverse lipiodol emulsions and CalliSpheres Beads in rabbit livers.

Drug Deliv. 2017-11

[8]
[Development of CalliSpheres® embolic microspheres].

Zhonghua Gan Zang Bing Za Zhi. 2016-7-20

[9]
Nine-year experience of doxorubicin-eluting beads chemoembolization for hepatocellular carcinoma.

Hepatobiliary Pancreat Dis Int. 2016-10

[10]
Conventional versus Doxorubicin-Eluting Beads Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: a Tertiary Medical Centre Experience in Malaysia.

Asian Pac J Cancer Prev. 2016

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索